Revenue and profitability
- Revenue: 8,500 CNY in QQ1 2025, YoY change: -55.26%; QoQ: N/A
- Gross Profit: 8,500 CNY, YoY change: -55.26%; QoQ: N/A
- Operating Income: -20,714,000 CNY; YoY change: +21.75% (improvement from prior period), QoQ change: +14.43%
- EBITDA: -19,976,750 CNY; EBITDARatio: -2232.56%
- Net Income: -19,099,500 CNY; YoY change: -5.88%; QoQ: +12.96%
- EPS: -0.13 CNY; Diluted EPS: -0.13 CNY; YoY: +23.53%; QoQ: +7.14%
- R&D Expense: 14,383,500 CNY; G&A Expense: 6,339,000 CNY; Total Operating Expenses: 20,722,500 CNY
- R&D intensity (R&D / Revenue): extreme given the quarter revenue base (R&D 14,383,500 vs Revenue 8,500)
Notes: The quarterly figures reflect a research-intensive business model typical of early-stage biopharma players, where substantial R&D outlays precede product commercialization. The ratio metrics shown (e.g., EBITDARatio) appear distorted by the very small revenue base in QQ1 2025; interpret margins in the context of pre-commercial pipeline investment.